Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer
Table 6
PSA progression in patients with various molecular subtypes.
AR-A
PAM50
GC score
Total
Low
High or average
Basal
Luminal
Low to average
High
N
9 (34.6%)
17 (65.4%)
15 (57.7%)
11 (42.3%)
11 (42.3%)
15 (57.7%)
26 (100%)
Time to PSA progression, months
Mean (SD)
36.4 (9.4)
29.0 (7.0)
31.8 (9.9)
31.2 (6.6)
34.1 (9.9)
29.7 (7.1)
31.6 (8.5)
Median
36.6
30.2
32.9
32.8
33.6
32.9
32.9
Range
20.3–56.6
17.7–39.4
17.8–56.6
17.7–39.4
17.8–56.6
17.7–38.6
17.7–56.6
PAM50: prediction analysis of microarray 50; SD: standard deviation.
